Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Study of Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of Extensive Stage Small Cell Lung Cancer

NCT05001412 is registered in ClinicalTrials.gov with Zhou Chengzhi as lead sponsor.

NCT NCT05001412
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05001412 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Study of Chemotherapy Combined With Camrelizumab and Apatinib in First-line Treatment of Extensive Stage Small Cell Lung Cancer
Lead sponsor
Zhou Chengzhi
Phase
Phase 1
Overall status
Unknown status
Start date
January 27, 2021
Completion date
January 25, 2024
Enrollment
36 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

extensive stage small cell lung cancer